TQB2934 not checked
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
FollowEvery change as it happens, and a Monday email
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “TQB2934 injection is a bispecific antibody targeting B-cell maturation antigen (BCMA) and Cluster of Differentiation 3 (CD3).”In the company’s words, NCT07569757 on ClinicalTrials.gov
- Tested for
- Multiple Myeloma (2 trials), Systemic Light Chain Amyloidosis
- Main trialPhase 3
- “This study is a randomized, open-label, multicenter Phase III clinical trial involving patients with relapsed/refractory multiple myeloma. The estimated total sample size is 260 cases, who will be randomly assigned in a 1:1 ratio to the test group and the control group. The primary objective of the study is to demonstrate the efficacy of TQB2934 for injection compared to the investigator-selected regimen in subjects with relapsed or refractory multiple myeloma (RRMM) by evaluating progression-free survival (PFS).”In the company’s words, NCT07569757 on ClinicalTrials.gov
Other drugs for Multiple Myeloma
- MezigdomideCelgene · Phase 3
- Anitocabtagene-autoleucelGilead (Kite) · Phase 3
- CM336Keymed Biosciences Co.Ltd · Phase 3
- IBI3003Innovent · Phase 3
- PomalidomideCelgene · Phase 3
- CevostamabRoche · Phase 3
Coming up3
- Oct 2027Phase 1 trial completes · ClinicalTrials.gov
- Dec 2028Phase 3 trial completes · ClinicalTrials.gov
- Feb 2029Phase 1/2 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials4
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Not yet recruiting | Dec 2028 | Clinical Study of TQB2934 Injection in Relapsed/Refractory Multiple Myeloma | |
| Phase 1/2Recruiting | Feb 2029 | Assessment of the Efficacy and Safety of Injectable TQB2934 (Subcutaneous Injection) in Systemic Light Chain Amyloidosis Patients | |
| Phase 1Recruiting | Oct 2027 | A Clinical Study Assessing the Subcutaneous Formulation of TQB2934 for Injection in Subjects With Malignant Plasma Cell Tumors | |
| Phase 1Unknown | Oct 2024 | A Clinical Trial of TQB2934 for Injection in Multiple Myeloma Subjects |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026